Enhancing PAP Adherence Among Spanish-speaking Hispanic Adults With OSA
Enhancing Positive Airway Pressure (PAP) Adherence Among Spanish-Speaking Hispanic Adults With Obstructive Sleep Apnea (OSA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Alexa Watach, PhD, RN
- Phone Number: 570-271-8663
- Email: awatach@nursing.upenn.edu
Study Locations
-
-
California
-
Fontana, California, United States, 92335
- Kaiser Permanent Southern California
-
Principal Investigator:
- Dennis X Hwang, MD
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
Principal Investigator:
- Mariana Ramirez, LCSW
-
Sub-Investigator:
- Perales Puchalt Jaime, PhD
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17821
- Geisinger
-
Principal Investigator:
- Bruno Saconi, PhD
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Principal Investigator:
- Amy M Sawyer, PhD
-
Sub-Investigator:
- A J Watach, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Spanish-speaking and reading
- Self-identified Hispanic
- Adults ≥ 18 years-old
- Males and females
- Moderate-severe OSA defined as AHI ≥15 events/hour using a hypopnea criterion of a 4% oxygen desaturation (AHI4%)
- Expected availability for the duration of the study (6 months from date of randomization)
- Ownership of smartphone with unlimited text messaging capability
- Referred to PAP treatment and able and willing to be treated with PAP
Exclusion Criteria:
- Other sleep apnea or nocturnal respiratory insufficiency or failure diagnosis other than OSA established by polysomnogram (PSG) or home sleep apnea test (HSAT)
- Requirement of supplemental oxygen or other non-invasive ventilation modality
- Women referred to PAP because of new-onset OSA with pregnancy as PAP treatment may be time-limited (enrolled women who become pregnant during the trial and are already on PAP treatment will not be excluded)
- Anticipated or scheduled bariatric surgery and/or referred to sleep evaluation by bariatric surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Automated Management (AM)
Receipt of text-based behavioral intervention
|
A tele-management intervention that will deliver text messages to participants via a bot - a computer program that simulates human outreach activity.
Programmed messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
|
|
No Intervention: Usual Care
Control group receiving usual care for obstructive sleep apnea
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Satisfaction
Time Frame: 6 months
|
Satisfaction with quality of care and the components of care (e.g., feedback, frequency, duration), relevance of the care to the individual and their needs, and overall satisfaction with care.
Assessed with the Client Satisfaction Questionnaire (CSQ-8).
The CSQ-8 scores range from 8 to 32, with higher values indicating higher satisfaction.
|
6 months
|
|
Acceptability
Time Frame: 6 months
|
Defined as the perception that a given treatment is agreeable, palatable, or satisfactory.
Assessed with the Acceptability of Intervention Measure (AIM; 4 items, Likert, 1-5, where 1 = "completely disagree" and 5 = "completely agree").
Higher scores indicate higher acceptability.
|
6 months
|
|
Appropriateness
Time Frame: 6 months
|
Defined as the perceived fit, relevance, or compatibility of a given treatment.
Assessed with the Intervention Appropriateness Measure (IAM; 4 items, Likert, 1-5, where 1 = "completely disagree" and 5 = "completely agree").
Higher scores indicate higher appropriateness.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment Rate
Time Frame: 6 months
|
Recruitment Rate computed at the end of the trial
|
6 months
|
|
Retention Rate
Time Frame: 6 months
|
Retention Rate computed at the end of the trial
|
6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Positive airway pressure (PAP) use from 3-6 months
Time Frame: 3-6 months
|
Hours of PAP use per 24 hours
|
3-6 months
|
|
PAP adherence based on modified Centers for Medicare & Medicaid Services (CMS) criteria
Time Frame: 6 months
|
Adherence yes/no using ≥4 hours/night and ≥70% of nights
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Alexa Watach, PhD, RN, Unniversity of Pennsylvania
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022-0810 (UW Madison)
- 375-SR-25 (Other Grant/Funding Number: American Academy of Sleep Medicine Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.